Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy ...

After 2 positive trials, low-dose colchicine’ got the FDA nod for CV reduction but then the CLEAR SYNERGY trial found no ...

Receiving an electronic reminder about influenza vaccination appeared to decrease COVID vaccination rates. Further study of ...

AstraZeneca is hopping aboard the pickleball craze as its serves up a new marketing push for its asthma med Fasenra. | ...

AstraZeneca ADR shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 83.

The U.K. government is proposing to raise the rebate rate under a national drug cost program, drawing complaints from the ...

In 2025, Cellectis will continue to focus its efforts and expenses on advancing its core clinical trials BALLI-01 and NATHALI ...

Nearly a decade after Erin Andrews was diagnosed with cervical cancer, the sportscaster told E! News she can't treat appointments as routine. But she does have a winning play to deal with the stress.

STORY: Stubborn inflation and President Donald Trump’s trade policies have rekindled fears of stagflation, a troubling ...

AstraZeneca is Thursday's pick for IBD 50 Growth Stocks To Watch as the biopharmaceutical name is holding up relatively well ...

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

AstraZeneca and Ionis Pharmaceuticals’ polyneuropathy drug has won approval in the European Union (EU), where it will be ...